Emil Bujak

Emil joined IP Group from HBM Partners, the advisor to HBM Healthcare Investments—a Swiss SIX listed healthcare investment company with approximately $2 billion in assets under management—where he progressed through roles including Analyst, Investment Advisor, and ultimately Partner responsible for private investments. He brings more than 15 years of experience in life sciences investing and research, with a track record of supporting companies across all stages of development, from company creation through clinical progress and into the public markets. His background combines rigorous scientific training, CFA level analytical discipline, and deep engagement with teams developing therapies for areas of significant unmet medical need.

Emil began his career as a registered pharmacist and later worked as an antibody technology specialist at Philochem, the Swiss subsidiary of Philogen. He holds a PhD and an MSc in Medicinal and Industrial Pharmaceutical Sciences from ETH Zurich and is also a Chartered Financial Analyst (CFA) charterholder.